Q4 Inc. to Report Second Quarter 2023 Results on August 9th
Q4 Inc. (TSX: QFOR), ("Q4" or the "Company"), the leading capital markets access platform, plans to release its second quarter 2023 financial results before the market opens on Wednesday, August 9, 2023. In conjunction with this release, the company will hold a video webcast led by Founder and CEO, Darrell Heaps, on the Q4 Virtual Events Platform at 9:30 a.m. ET on August 9, 2023.
Q2 2023 Earnings Release and Conference Call Details
Participants can register in advance or access the webcast live at https://events.q4inc.com/attendee/399373593. Supplemental materials will be available at least fifteen minutes prior to the start of the event. A replay of the webcast will be available at investors.Q4inc.com shortly after the event concludes.
Audience questions will be taken real-time via the Q4 Platform. Investors can also submit their questions in advance to ir@q4inc.com or via our IR website. We will do our best to respond to your questions either on the webcast, if time permits, or shortly thereafter. We appreciate your interest.
About Q4 Inc.
Q4 Inc. (TSX: QFOR) is the leading capital markets access platform that is transforming how issuers, investors, and the sell-side efficiently connect, communicate, and engage with each other.
The Q4 Platform facilitates interactions across the capital markets through IR website products, virtual events solutions, engagement analytics, investor relations CRM, shareholder and market analysis, surveillance, and ESG tools. The Q4 Platform is the only holistic capital markets access platform that digitally drives connections, analyzes impact, and targets the right engagement to help public companies work faster and smarter.
The company is a trusted partner to more than 2,600 public companies globally, including many of the most respected brands in the world, and maintains an award winning culture where team members grow and thrive.
Q4 is headquartered in Toronto, with offices in New York and London. Learn more at investors.Q4inc.com.
Source: Q4 INC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230719130019/en/
Contact information
Investors:
Edward Miller
Director, Investor Relations
(437) 291-1554
ir@q4inc.com
Media:
Heather Noll
Corporate Communications Manager
media@q4inc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Analyze Contracts Like a Lawyer - Wordsmith’s First Pass Unlocks Legal Insight for Everyone8.11.2024 00:54:00 EET | Press release
“Contracts often hold up business because legal teams are stretched too thin,” said Ross McNairn, CEO of Wordsmith. “First Pass allows anyone from the legal, commercial or other teams to quickly identify risks and key terms, helping move things forward.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241108164624/en/ Wordsmith's First Pass lets you review contracts in minutes, not hours. (Graphic: Business Wire) This is a glimpse at the future of legal AI agents. Taking a very specific task end-to-end and making it trivial for anyone to trigger. Try It for Free Users can access First Pass for free by creating an account at wordsmith.ai and then uploading the relevant agreement to the web, or simply email standard agreements—like NDAs—to nda@wordsmith.ai. Over the coming weeks, Wordsmith will be expanding this to many other agreement types. End-to-End AI Analysis—More Than Just Contracting What makes First Pass revolutionary
Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research7.11.2024 23:01:00 EET | Press release
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an agreement to acquire the DNA and RNA business of Officinae Bio. The acquisition is expected to expand Maravai and TriLink BioTechnologies' ability to assist customers in developing innovative nucleic acid-based therapies. Based in Venice, Italy, Officinae Bio is a privately held technology company with a proprietary digital platform to support the biological design of therapeutics. The novel technology enables rapid prototyping of mRNA candidates to test diverse combinations of CAP analogs, chemistry modifications, and sequence designs for client discovery programs. Officinae Bio’s portfolio of technology and services complements Maravai’s nucleic acid production services and is expected to provide customers with significant benefits as they bring new and innovative therapies to patients in need. “Officinae Bio’s uniqu
IonQ to Increase Performance and Scale of Quantum Computers with Photonic Integrated Circuits in Collaboration with imec7.11.2024 23:00:00 EET | Press release
IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today that it is developing photonic integrated circuits (PICs) and chip-scale ion trap technology for trapped ion quantum computing in partnership with imec, a world-renowned R&D center in nanoelectronics and digital technologies. By optimizing the design, production, and integration of chip-scale photonic devices and ion traps for scalable and high-performance quantum computers, the developments aim to push the boundaries of quantum computing performance. Traditional trapped ion quantum computing approaches rely on bulk optics for laser light modulation, delivery, and photon collection. By moving traditional bulk optical components into integrated photonic devices, IonQ aims to reduce overall hardware system size and cost, increase qubit count, and improve system performance and robustness. Chip-scale optical technologies and IonQ’s tight integration with imec’s trap manufacturing and packing are expected to ope
BM3EAC Corp. Termination of Discussions Regarding Proposed Business Combination With Arkon Energy7.11.2024 19:29:00 EET | Press release
BM3EAC Corp. (the “Company”), a shell company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., hereby announces the termination of the discussions with Arkon Energy Ohio LLC (now Arkon Energy US Holdco LLC) (“Arkon”) regarding a potential transaction, including a business combination, initially announced on 21 February 2024 (the “Potential Business Combination”). After careful consideration, the Company and Arkon have determined that the current market conditions are not conducive to proceeding with the Potential Business Combination. IMPORTANT INFORMATION This press release may contain information that qualifies or may have qualified as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or s
Brenus Pharma Publishes Promising Proof of Concept Results of their Therapeutic Platform in the Scientific Frontiers in Oncology Journal. (1)7.11.2024 19:00:00 EET | Press release
Brenus Pharma has announced the publication of a scientific article describing its new “off-the-shelf” cancer treatment in “Frontiers in Oncology” Section Cancer Immunity and Immunotherapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107407975/en/ Brenus’ platform mimics patients’ relapsing conditions in lab, to educate the immune system against tumors evolution with the largest panel of multi-specific targets available. Its lead candidate is a proteomic-guided immunotherapy, designed to treat patients with advanced or metastatic CRC. Results show that the murine surrogate treatment inhibits tumor growth and improves survival of treated mice bearing tumors. It has also shown efficacy in a PD1-resistant model, with an increased infiltration of CD8+T cells in cold tumors, associated with strong safety data. Indeed, the treatment’s in vitro exposition to standards of careinduces the expression of cancer-related proteins l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom